在外围动脉疾病中SDF-1α mRNA治疗
Tinghong Zhang1,2, Binqiang Zhu1,2, Shijie Deng1,2
1State Key Laboratory of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Angiogenesis
|May 2, 2025
概括
通过DOPE-脂质纳米颗粒 (LNPs) 输送的流体细胞衍生因子-1α (SDF-1α) mRNA疗法,有效地促进缺血组织中的血管再生. 这种新的方法在治疗外围动脉疾病 (PAD) 和其他血管疾病方面表现有前途.
科学领域:
- 生物医学工程 生物医学工程
- 分子医学是分子医学.
- 再生医学是一种再生医学.
背景情况:
- 干细胞衍生因子-1α (SDF-1α) 是治疗性血管生成的关键标,用于诸如外周动脉疾病 (PAD) 等缺血性疾病.
- 以前的SDF-1α蛋白或等离子体基因疗法的临床应用遇到了局限性.
- 使者RNA (mRNA) 疗法为蛋白质替代策略提供了一个有希望的替代方案.
研究的目的:
- 开发和评估DOPE-脂质纳米颗粒 (LNP) 封装SDF-1αmRNA (LNP@SDF-1α) 以实现高效的基因传递和治疗性血管生成.
- 评估LNP@SDF-1α在缺血性疾病的体外和体内模型中的益血管性潜力.
主要方法:
- 开发DOPE脂质纳米颗粒 (LNP) 封装SDF-1α mRNA.
- 使用人类静脉内皮细胞 (HUVECs) 进行体外研究,以评估内皮迁移,管形成和单细胞粘附.
- 在体内研究包括鼠Matrigel插头模型,小鼠后肢缺血模型,激光斑点对比成像,免疫光染色和血管蛋白质分析.
主要成果:
- 在体外,LNP@SDF-1α显著增强了内皮细胞功能 (迁移,管形成,单细胞粘附).
- 在体内,LNP@SDF-1α在Matrigel插头模型中促进了血管新生,并在小鼠后肢缺血模型中加速了血流恢复.
- 治疗导致毛细血管和动脉的密度增加,对益血管性因子 (VEGF,Ang-1) 的上调和对抗血管性因子的下调,没有显著的器官毒性.
结论:
- 通过DOPE-LNPs提供的SDF-1α mRNA疗法有效地促进了血管再生和缺血组织中的血液 perfusion.
- 这种方法增强了血管生成和动脉生成,为周围动脉疾病 (PAD) 提供了可行的治疗选择.
- 这项研究强调了基于mRNA的疗法在治疗各种缺血性疾病方面的更广泛潜力.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
01:30Peripheral Artery Disease I: Introduction
663
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
663
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
773
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
773
01:27Peripheral Artery Disease III: Interprofessional Care
659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659
01:26Peripheral Artery Disease IV: Nursing Management
714
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
714